dexamethasone (or equivalent corticosteroids) plus optional cyclophosphamide. Despite the setback, Amgen subsidiary Onyx Pharmaceuticals ( ONXX ) President Pablo J. Cagnoni says, "While it is unfortunate that the FOCUS study did not meet its primary
blossoming oncology space. It picked up the proteasome inhibitor just under a year ago, along with the rest of Onyx Pharmaceuticals , for about $9.5 billion. While second quarter sales reached a healthy $78 million, it's still Complete
Bayer HealthCare Pharmaceuticals ( OTCPK:BAYRY -2.4% ) ( OTCPK:BAYZF -1.7% ) and development partner Onyx Pharmaceuticals ( AMGN -0.3% ) report that the 537-patient Phase 3 clinical trial evaluating the safety and efficacy of Nexavar
huge sums for smaller innovators. For example, last summer, Amgen upped its offer to buy cancer drug maker Onyx Pharmaceuticals from $9.3 billion to $9.7 billion. Such deals — along with generally healthy balance sheets and access to capital among life sciences companies
sclerosis compound. [TICKER:AMGN] Amgen as well, which recently announced an acquisition of [TICKER:VRTX] Onyx Pharmaceuticals , has been strong from an earnings perspective and a stock perspective. And a name like Vertex, which has been
with its internal prospects last quarter when it decided to make the $10 billion debt-funded acquisition of Onyx Pharmaceuticals ONXX (rating: SUS, no moat). This acquisition will boost Amgen's top-line growth by nearly 200 basis points
Aug 26 (Reuters) - Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood...
After several weeks of media speculation, Amgen finally announced the acquisition of Onyx Pharmaceuticals for $125 per share, valuing the company at $10.4 billion (or $9.7 billion net of cash). As we stated previously, we
NEW YORK (Reuters) - Amgen Inc, the drugmaker in advanced discussions to buy Onyx Pharmaceuticals Inc, has asked Onyx for some of the data from an ongoing trial on the company's new blood cancer...
(Adds Onyx Pharmaceuticals , Telediffusion de France, TPG Capital and others)